news
Could GSK myelofibrosis treatment gain EU-first approval?
If approved, momelotinib will be the first treatment in the EU indicated for myelofibrosis patients with moderate to severe anaemia.
List view / Grid view
myelofibrosis
news
First treatment for myelofibrosis with anaemia approved
The US Food and Drug Administration (FDA) has granted approval of a treatment for anaemic patients with a rare blood cancer.
news
$1.7b acquisition to develop rare haematology therapy
When CTI BioPharma is acquired by Swedish Orphan Biovitrum AB (Sobi), the companies intend to advance an oral kinase inhibitor treatment for a rare haematological disease.
news
EMA accepts momelotinib marketing application
The marketing authorisation application for momelotinib, a new oral treatment for myelofibrosis has been accepted by the EMA.
news
GSK will acquire Sierra Oncology to strengthen haematology arsenal
GlaxoSmithKline has announced the agreed $1.9bn acquisition of biopharmaceutical company Sierra Oncology, which specialises in treatments for rare forms of cancer.
news
EMA recommends 15 medicines for approval following December meeting
The EMA's human medicines committee has released its results for the December meeting, suggesting which therapies should receive marketing authorisation.
news
Bristol-Myers Squibb completes acquisition of Celgene
After regulatory approval, Bristol-Myers Squibb has announced its successful acquisition of Celgene, completing the merger.
